These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1586396)

  • 1. [Opiate addiction. Pharmacologic and biochemical aspects].
    Herz A; Shippenberg TS; Bals-Kubik R; Spanagel R
    Arzneimittelforschung; 1992 Feb; 42(2A):256-9. PubMed ID: 1586396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats.
    Bals-Kubik R; Ableitner A; Herz A; Shippenberg TS
    J Pharmacol Exp Ther; 1993 Jan; 264(1):489-95. PubMed ID: 8093731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bidirectional effects of opioids in motivational processes and the involvement of D1 dopamine receptors.
    Herz A
    NIDA Res Monogr; 1988; 90():17-26. PubMed ID: 2855853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors.
    Shippenberg TS; Bals-Kubik R; Herz A
    J Pharmacol Exp Ther; 1993 Apr; 265(1):53-9. PubMed ID: 8386244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.
    Kreek MJ; Schluger J; Borg L; Gunduz M; Ho A
    J Pharmacol Exp Ther; 1999 Jan; 288(1):260-9. PubMed ID: 9862779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid reward mechanisms: a key role in drug abuse?
    Herz A
    Can J Physiol Pharmacol; 1998 Mar; 76(3):252-8. PubMed ID: 9673788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of the mesolimbic dopamine system in mediating the aversive effects of opioid antagonists in the rat.
    Shippenberg TS; Bals-Kubik R
    Behav Pharmacol; 1995 Mar; 6(2):99-106. PubMed ID: 11224316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine release in the nucleus accumbens during heroin self-administration is modulated by kappa opioid receptors: an in vivo fast-cyclic voltammetry study.
    Xi ZX; Fuller SA; Stein EA
    J Pharmacol Exp Ther; 1998 Jan; 284(1):151-61. PubMed ID: 9435173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid abuse and brain gene expression.
    Przewlocki R
    Eur J Pharmacol; 2004 Oct; 500(1-3):331-49. PubMed ID: 15464044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mu- and delta-opioid receptor-mediated inhibition of adenylate cyclase activity stimulated by released endogenous dopamine in rat neostriatal slices; demonstration of potent delta-agonist activity of bremazocine.
    Heijna MH; Hogenboom F; Portoghese PS; Mulder AH; Schoffelmeer AN
    J Pharmacol Exp Ther; 1989 Jun; 249(3):864-8. PubMed ID: 2543814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neurobiological principles of drug dependence. Exemplified by opioids and psychostimulants].
    Herz A
    Nervenarzt; 1995 Jan; 66(1):3-14. PubMed ID: 7885510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Place-conditioning properties of mu, kappa, and sigma opioid agonists.
    Iwamoto ET
    Alcohol Drug Res; 1985-1986; 6(5):327-39. PubMed ID: 3011025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of opioid dependence and interaction between opioid receptors.
    Suzuki T; Kishimoto Y; Ozaki S; Narita M
    Eur J Pain; 2001; 5 Suppl A():63-5. PubMed ID: 11798220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotational behavior mediated by dopaminergic and nondopaminergic mechanisms after intranigral microinjection of specific mu, delta and kappa opioid agonists.
    Matsumoto RR; Brinsfield KH; Patrick RL; Walker JM
    J Pharmacol Exp Ther; 1988 Jul; 246(1):196-203. PubMed ID: 2839661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area.
    Latimer LG; Duffy P; Kalivas PW
    J Pharmacol Exp Ther; 1987 Apr; 241(1):328-37. PubMed ID: 3033208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delta opioid-like discriminative stimulus effects of mu opioids in pigeons discriminating the delta opioid BW373U86 from saline.
    Picker MJ; Cook CD
    Behav Pharmacol; 1998 Jul; 9(4):319-28. PubMed ID: 10065920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antinociception induced by intrathecal coadministration of selective adenosine receptor and selective opioid receptor agonists in mice.
    De Lander GE; Keil GJ
    J Pharmacol Exp Ther; 1994 Feb; 268(2):943-51. PubMed ID: 8114009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous opioid systems and alcohol addiction.
    Herz A
    Psychopharmacology (Berl); 1997 Jan; 129(2):99-111. PubMed ID: 9040115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid receptor subtypes differentially modulate serotonin efflux in the rat central nervous system.
    Tao R; Auerbach SB
    J Pharmacol Exp Ther; 2002 Nov; 303(2):549-56. PubMed ID: 12388635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Delta(9)-THC-induced increase of cortical and hippocampal acetylcholine release by micro opioid and D(1) dopamine receptors.
    Pisanu A; Acquas E; Fenu S; Di Chiara G
    Neuropharmacology; 2006 May; 50(6):661-70. PubMed ID: 16427098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.